Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
Spyre Therapeutics (NASDAQ: SYRE) announced poster presentations at United European Gastroenterology Week (UEGW) 2025, according to the PR dated Oct 5, 2025.
The PR states interim Phase 1 data for SPY002 show it was well tolerated through six months, has a differentiated PK profile that the company says could support quarterly (Q3M) or twice‑yearly (Q6M) dosing, and suppressed free TL1A through 24 weeks. The company also reported preclinical combination data where α4β7 + TL1A, α4β7 + IL‑23, and TL1A + IL‑23 combinations outperformed monotherapies in rodent TNBS colitis models. Posters and session details are available via the UEGW program, per the PR.
Spyre Therapeutics (NASDAQ: SYRE) ha annunciato presentazioni poster alla United European Gastroenterology Week (UEGW) 2025, secondo il comunicato stampa datato 5 ottobre 2025.
Il comunicato indica che i dati interimi di fase 1 per SPY002 hanno mostrato una buona tollerabilità fino a sei mesi, hanno un profilo farmacocinetico differenziato che l’azienda ritiene potrebbe supportare una somministrazione quarterly (Q3M) o due volte l'anno (Q6M), e hanno sopresso TL1A libero fino a 24 settimane. L’azienda ha inoltre riportato dati preclinici di combinazione in cui le combinazioni α4β7 + TL1A, α4β7 + IL‑23 e TL1A + IL‑23 hanno superato la monoterapia nei modelli di colite da TNBS nei roditori. Poster e dettagli delle sessioni sono disponibili tramite il programma UEGW, secondo il comunicato.
Spyre Therapeutics (NASDAQ: SYRE) anunció presentaciones en póster en la United European Gastroenterology Week (UEGW) 2025, según el comunicado de prensa con fecha del 5 de octubre de 2025.
El comunicado indica que los datos interinos de Fase 1 para SPY002 mostraron buena tolerancia hasta seis meses, tienen un perfil PK diferenciado que la empresa dice podría soportar una dosificación trimestral (Q3M) o semestral (Q6M), y suprimió TL1A libre hasta 24 semanas. La empresa también reportó datos preclínicos de combinación donde las combinaciones α4β7 + TL1A, α4β7 + IL‑23, y TL1A + IL‑23 superaron a las monoterapias en modelos de colitis TNBS en roedores. Los pósters y detalles de las sesiones están disponibles a través del programa UEGW, según el PR.
Spyre Therapeutics (NASDAQ: SYRE)는 2025년 United European Gastroenterology Week (UEGW) 2025에서 포스터 발표를 한다고 2025년 10월 5일자 PR에 따라 발표했다.
PR에 따르면 SPY002의 1상 중간 데이터가 6개월 동안 잘 내약성이 있음을 보였고, 차별화된 약동학(PK) 프로파일을 가지고 있어 회사가 분기별(Q3M) 또는 반년별(Q6M) 투여를 뒷받침할 수 있을 것으로 보이며, 24주 동안 자유 TL1A를 억제했다. 또한 α4β7 + TL1A, α4β7 + IL‑23, TL1A + IL‑23 조합이 쥐 TNBS 대장염 모델에서 단일 요법보다 우수했다는 전임상 조합 데이터도 보고되었다. 포스터와 세션 세부정보는 PR에 따른 UEGW 프로그램에서 확인할 수 있다.
Spyre Therapeutics (NASDAQ: SYRE) a annoncé des présentations par affiches lors de la United European Gastroenterology Week (UEGW) 2025, selon le communiqué de presse daté du 5 octobre 2025.
Le communiqué indique que les données intermédiaires de phase 1 pour SPY002 montrent une bonne tolérance jusqu’à six mois, disposent d’un profil PK différencié que l’entreprise dit pouvoir soutenir une posologie trimestrielle (Q3M) ou semestrielle (Q6M), et ont supprimé TL1A libre jusqu’à 24 semaines. L’entreprise a également rapporté des données précliniques de combinaison où les combinaisons α4β7 + TL1A, α4β7 + IL‑23 et TL1A + IL‑23 surpassent les monothérapies dans des modèles de colite TNBS chez les rongeurs. Les affiches et les détails des sessions sont disponibles via le programme UEGW, selon le PR.
Spyre Therapeutics (NASDAQ: SYRE) hat Posterpräsentationen bei der United European Gastroenterology Week (UEGW) 2025 angekündigt, gemäß der Pressemitteilung vom 5. Oktober 2025.
Die Pressemitteilung besagt, dass die Zwischendaten der Phase-1-Studie für SPY002 eine gute Verträglichkeit über sechs Monate zeigen, über ein differenziertes PK-Profil verfügen, das das Unternehmen als Unterstützung für quartalsweise (Q3M) oder zweimal jährlich (Q6M) Dosierung ansieht, und bis zu 24 Wochen freies TL1A unterdrückt. Das Unternehmen berichtete außerdem über präklinische Kombinationsdaten, bei denen α4β7 + TL1A, α4β7 + IL‑23 und TL1A + IL‑23 Kombinationen Monotherapien in Nagetiermodellen mit TNBS-Colitis übertrafen. Poster und Sitzungsdetails sind über das UEGW-Programm verfügbar, gemäß dem PR.
Spyre Therapeutics (NASDAQ: SYRE) أعلنت عن عروض ملصقات خلال أسبوع الجهاز الهضمي الأوروبي الموحد (UEGW) 2025، وفق بيان صحفي بتاريخ 5 أكتوبر 2025.
يذكر البيان أن بيانات المرحلة 1 الوسيطة لـ SPY002 أظهرت تحملًا جيدًا حتى ستة أشهر، ولها ملف PK مميز تقول الشركة إنه قد يدعم تنظيم جرعات ربع سنوي (Q3M) أو نصف سنوي (Q6M)، وأنه تم تثبيط TL1A الحر حتى 24 أسبوعًا. كما أبلغت الشركة عن بيانات تركيبية ما قبل السريرية حيث تفوقت تركيبات α4β7 + TL1A، α4β7 + IL‑23، وTL1A + IL‑23 على العلاجات الأحادية في نماذج مرض الالتهاب المعوي TNBS لدى القوارض. يمكن الوصول إلى الملصقات وتفاصيل الجلسات عبر برنامج UEGW، وفقًا للبيان.
Spyre Therapeutics (NASDAQ: SYRE) 根据2025年10月5日的新闻稿，宣布将在2025年欧洲胃肠病学周（UEGW）上进行海报展示。
新闻稿称，SPY002的阶段I中期数据在六个月内耐受性良好，具有差异化的药代动力学（PK）特征，公司表示这可能支持< b>每季度（Q3M）或每半年（Q6M）给药，并在24周内抑制游离TL1A。公司还报告了前临床组合数据，其中< b>α4β7 + TL1A、α4β7 + IL‑23，以及TL1A + IL‑23组合在啮齿动物的TNBS结肠炎模型中优于单药治疗。海报和会话详情可通过PR中的UEGW程序获得。
- None.
- None.
Insights
Phase 1 six‑month data show SPY002 is tolerated, durable, and enables infrequent dosing; preclinical combos improve efficacy versus monotherapies.
The article states interim Phase 1 results for SPY002 show it is well tolerated, suppresses free TL1A through 24 weeks, and has a pharmacokinetic profile consistent with Q3M or Q6M maintenance dosing. These are concrete early clinical signals about safety, target engagement, and dosing cadence rather than efficacy in patients.
The release also reports preclinical mouse data where combined inhibition (α4β7 + TL1A, α4β7 + IL‑23, TL1A + IL‑23) outperformed monotherapies, which the article frames as additional rationale for the ongoing SKYLINE‑UC Phase 2 study. Together, the clinical and preclinical items validate the biological hypothesis and support continued clinical development, but they do not prove clinical benefit in patients beyond safety and biomarker suppression.
What it means: the program cleared important early checkpoints for tolerability, PK, and target suppression, reducing near‑term technical risk; why it matters: less frequent dosing and validated combination rationale can materially affect trial design and patient adherence if later efficacy is shown. Monitorable item: watch for subsequent clinical readouts beyond 24 weeks and top‑line results from the SKYLINE‑UC Phase 2 study.
WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced scientific presentations at the UEGW Congress.
“We are excited to share follow-up data out to six months from our Phase 1 study of SPY002, our potential best-in-class anti-TL1A agent in development for IBD. The data continue to show SPY002 is well tolerated, has a differentiated PK profile supporting quarterly or twice-yearly dosing, and suppresses free TL1A through 24 weeks,” said Josh Friedman, M.D., Ph.D., SVP of Clinical Development at Spyre. “Additionally, we are pleased to share new preclinical data demonstrating that each of our combination programs (α4β7 + TL1A, α4β7 + IL-23, and TL1A + IL-23) exhibit superior efficacy relative to constituent monotherapies in rodent TNBS-induced colitis models, providing additional validation for our ongoing SKYLINE-UC Phase 2 study.”
The poster will be available for viewing during the UEGW Congress, and details are as follows:
Title: Interim Phase 1 Results for SPY002, a Novel Half-Life Extended Monoclonal Antibody Targeting TL1A, Suggests a Potential for Q3M or Q6M Maintenance Dosing for Inflammatory Bowel Disease
Authors: Y. Vugmeyster, S. Sloan, JD Lu, K. Hew, P. Patel, C. Sheldon, D. Nguyen, R. McLean, M. Huyghe, B. Connolly, B. Wang, M. Kennedy, M. Rose, E. Svejnoha, J. Friedman
Title: Combined Inhibition of Integrin β7 and TL1A, Integrin β7 and IL-23, or TL1A and IL-23 Are Superior to Their Constituent Monotherapies in Mouse TNBS-Induced Colitis
Authors: M. Siegel, J. Friedman, E. Lewis, D. Giles, A. Spencer
Full session details can be accessed via the UEGW program.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.
For more information, please visit http://spyre.com.
Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, concerning Spyre and other matters. These forward-looking statements include, but are not limited to, express or implied statements relating to Spyre's management team's expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, Spyre’s ability to achieve the expected benefits or opportunities with respect to its pipeline of product candidates such as the potential efficacy, tolerability, convenience, commercial viability, dosing regimen and safety profile of SPY002 in humans, including the potential for a quarterly or twice yearly dosing profile; the potential for SPY002 to become a best-in-class therapy for IBD; the potential consistency of the SPY002 Phase 2 trial final data readouts with interim Phase 1 results; and the potential therapeutic benefits of Spyre’s product candidates as monotherapies or in combinations and their extended half-life, including the expected duration of half-life in comparison to competitor products and the potential potency, efficacy and convenience compared to today’s standard of care. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "opportunity," "potential," "milestones," "pipeline," "can," "goal," "aim," "strategy," "target," "seek," "anticipate," "achieve," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "predict," "project," "should," "will," "would," and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Spyre will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Spyre's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited, uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with the Company’s interpretation of data and the Company’s clinical trials for its product candidates, including our plans for and timing of cohort initiation for combination therapy arms for the ongoing SKYLINE-UC Phase 2 platform trial across different jurisdictions; the potential for final data not being consistent with or different than the interim data reported for our programs; the potential impact of Trump Administration policies and changes in law on our business; and those uncertainties and factors described under the heading "Risk Factors," "Risk Factor Summary" and "Note about Forward-Looking Statements" in Spyre's most recent Annual Report on Form 10-K, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that the Company has filed or will file with the SEC, as well as discussions of potential risks, uncertainties, and other important factors included in other filings by Spyre from time to time. Should one or more of these risks or uncertainties materialize, or should any of Spyre's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Spyre does not undertake or accept any duty to make any updates or revisions to any forward-looking statements. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in Spyre.
For Investors:
Eric McIntyre
VP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com
For Media:
Josie Butler, 1AB
josie@1abmedia.com
FAQ
What SPY002 data did Spyre present at UEGW 2025 (SYRE)?
Does Spyre say SPY002 could be dosed quarterly or twice yearly (SYRE)?
What preclinical combination results did Spyre report at UEGW 2025 for SYRE?
How do the UEGW posters relate to Spyre's SKYLINE‑UC Phase 2 study (SYRE)?
When and where can investors view Spyre's UEGW posters (SYRE)?
Are there any safety or efficacy numerical readouts for SPY002 disclosed in the PR (SYRE)?
